← All trials
NCT06846307
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Jan 29, 2024
- Completion date
- Jan 31, 2024
- First posted
- Feb 26, 2025
- Last posted
- Mar 3, 2025
- Enrollment
- 32
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Diponegoro UniversityLead sponsor
- Diponegoro UniversitySponsor investigator
- Diponegoro UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.